AC164204 and AC164209 are therefore single molecular entities that can harness the anti-diabetic properties of incretin monotherapy with significantly greater weight loss in a single compound, thus potentially meeting the greatly unmet medical need for pharmacological interventions for Metabolic Syndrome. This evidence concerns the gene GCG and metabolic syndrome.